Sign in

    Hannah Tran

    Vice President and Equity Research Analyst at Wolfe Research

    Hannah Tran is a Vice President and Equity Research Analyst at Wolfe Research, specializing in the coverage of the specialized consumer finance sector, with notable analysis of companies such as Synchrony, Discover Financial, and Ally Financial. With a career in equity research beginning at Wolfe Research in 2018, she brings a track record of issuing high-quality investment recommendations, evidenced by a TipRanks success rate above 62% and an average annualized return of over 7%. Before joining Wolfe Research, Tran worked in financial research roles at Citi, and she currently holds FINRA Series 7, 63, and 86/87 licenses. Her work has been recognized in industry rankings, and she is commended for her data-driven insights and independent stock calls.

    Hannah Tran's questions to Intellia Therapeutics (NTLA) leadership

    Hannah Tran's questions to Intellia Therapeutics (NTLA) leadership • Q1 2025

    Question

    Hannah Tran, on behalf of Andy Chen, inquired about the company's consideration of non-dilutive financing options to extend its cash runway beyond the first half of 2027.

    Answer

    Chief Financial Officer Ed Dulac confirmed that multiple options are on the table. He highlighted that upcoming clinical and regulatory milestones will create opportunities for favorable capital raises. Potential levers include strategic collaborations for assets like NTLA-2002, royalty transactions as commercialization approaches, and venture or term debt structures.

    Ask Fintool Equity Research AI